<DOC>
	<DOCNO>NCT02548494</DOCNO>
	<brief_summary>The management goal diabetic ketoacidosis ( DKA ) pediatric new-onset type 1 diabetes ( T1DM ) population fluid electrolyte repletion , insulin administration , correction acidosis order stabilize patient . Traditionally , rapid-acting insulin IV infusion begin immediately continued acidosis correct hyperglycemia normalize . Once acidosis correct , patient able transition subcutaneous insulin regimen . The role subcutaneous long-acting insulin glargine acute treatment DKA extensively study . While give glargine treatment DKA become common place , study examine potential risk benefit use . This study investigate effect early administration glargine DKA patient newly diagnose TIDM . The design study prospective , double-blind study child age 2-21 admitted hospital DKA new diagnosis T1DM . The control group receive traditional method treatment DKA , include placebo subcutaneous injection . The study group receive treatment , supplement subcutaneous glargine injection .</brief_summary>
	<brief_title>Early Administration Long-acting Insulin Treatment Diabetic Ketoacidosis Pediatric New-onset Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Ketosis</mesh_term>
	<mesh_term>Acidosis</mesh_term>
	<mesh_term>Diabetic Ketoacidosis</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Newonset T1DM Hyperglycemia &gt; 200 mg/dl Bicarbonate â‰¤ 15 mmol/L pH &lt; 7.3 Ketonemia Ketonuria Glucosuria Admission PICU ( Pediatric Intensive Care Unit ) Ages 121 year Known T1DM ( Type 1 Diabetes ) Patients receive glargine within last 24 hour Patients sepsis</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>